Effective January 1, 2026, the South Korean government abolished the 10% VAT refund program for foreign patients undergoing cosmetic surgery and dermatology procedures. The change was announced by the Ministry of Economy and Finance in mid-2025 as part of the year\'s tax reform plan and ratified through the standard legislative process. It is the most significant policy change in Korean medical tourism in nearly a decade.
For international patients planning a Korean cosmetic-surgery trip in 2026 and beyond, here is what actually changed and how to think about it.
What was abolished
The discontinued program, introduced in April 2016, allowed foreign tourists to claim a refund of approximately 100,000–200,000 won (USD 72–144) per qualifying procedure when paying VAT on cosmetic and dermatological treatments. The refund was applied at participating clinics and processed at airport tax-refund counters on departure.
From 1 January 2026:
- No new VAT refunds will be issued for cosmetic or dermatological procedures performed in 2026 or later.
- The 10% VAT remains baked into clinic pricing — the consumer does not separately recover it.
- Procedures paid for in 2025 may still be eligible for refund processing into early 2026 (typically January through March), provided the patient departs Korea within 3 months of the procedure date.
Why the program was ended
Government rationale, as published in the policy notice:
- The original 2016 measure was framed as temporary, designed to stimulate medical tourism during the early Korean Wave era.
- Foreign patient volumes and revenue have grown more than fourfold over the program\'s lifetime, with cosmetic and dermatological procedures dominant in the mix.
- Officials concluded the policy had achieved its purpose; further extension was not deemed necessary.
- Observers note an additional dimension: cosmetic surgery is taxed in Korea (unlike most therapeutic medical care), and the VAT refund created an asymmetry with domestic patients who pay the full tax.
What the practical impact looks like
For individual procedures
The refund averaged roughly $72–$144 per procedure under the program. Practical impact:
- A patient receiving USD 1,000 worth of skin treatments lost roughly $90 in refund value.
- A patient receiving a USD 8,000 rhinoplasty lost the typical capped refund value (the cap limited refunds to $144 per procedure regardless of price).
- For lower-cost dermatology treatments, the VAT refund mattered proportionally more; for major surgical procedures, the refund was a small share of total cost.
For trip economics
Across multiple procedures during a single trip, the cumulative refund could reach $300–$600 for some patient itineraries. That figure is meaningful for some patients and immaterial for others. As a percentage of overall trip cost (procedure + accommodation + flights), the refund typically represented 1–3%.
How clinics are responding
Three patterns observed in the early weeks of 2026:
- Reframed package pricing — many clinics that had separately advertised post-refund pricing have updated their international-patient quotes to reflect inclusive pricing without the refund.
- Selective discounting — some Gangnam clinics have introduced modest international-patient promotional pricing, partially absorbing the lost refund value to maintain competitive positioning.
- Service-level competition — accommodation, translator, and transfer add-ons are being emphasized as distinguishing features in a market where the headline price savings are smaller.
How this changes the cross-border math
The cost competitiveness of Korean cosmetic surgery vs. peer destinations changes only modestly:
- Korea remains substantially cheaper than the United States and Western Europe for most procedures.
- Versus Turkey for hair transplants and rhinoplasty, the per-procedure cost gap was already wider than the VAT refund. Turkey\'s cost advantage is unaffected by Korea\'s VAT change.
- Versus Thailand for body procedures, similar story — Thai pricing was already comparable, and the VAT refund was not the deciding factor for most patients.
- The patients most affected are those for whom Korea\'s appeal was specifically the post-refund pricing on smaller dermatology and injectable spending.
What this signals about medical-tourism policy
The VAT refund change is one of several signals about Korean medical-tourism strategy in 2026:
- Continued tightening of cosmetic-treatment marketing language (the 2025 MFDS exosome ad ban).
- Maturing focus on quality and clinical regulation over volume incentives.
- Increased KHIDI registration emphasis as a quality differentiator.
- Continued growth in higher-end medical tourism (genuine medical care, complex revisions) over volume cosmetic procedures.
Practical implications for 2026 planning
For patients planning a 2026 Korea trip:
- Update your budget — add roughly 10% to the post-refund price you saw quoted on 2024–2025 information sources.
- Compare current package quotes — clinics are adjusting pricing; current quotes are more reliable than older reviews.
- Negotiate value-added services — accommodations, follow-up visits, lymphatic massage, and remote post-op support are valuable add-ons that some clinics may include to remain competitive.
- Don\'t overweight the change — a 1–3% trip-cost difference rarely changes the surgical decision; clinic and surgeon choice still dominate the outcome.
What hasn\'t changed
- The core technical and surgical strengths that drew international patients to Korea remain intact.
- KHIDI medical-tourism registration continues; consumer-protection mechanisms are unchanged.
- The CCTV-in-OR and ghost-surgery rules continue to provide additional patient safeguards.
- Korean clinic remote-followup norms (developed during the pandemic and now standard) continue.
- Specialty-board credentialing for surgeons is unchanged.
Bottom line
The 2026 VAT-refund elimination is a meaningful policy shift but not a market-defining one. Korean cosmetic surgery remains globally competitive on price, technique, and surgeon quality. The headline-grabbing change affects per-trip economics by a modest margin and does not alter the fundamental value proposition for patients pursuing complex facial work, rhinoplasty revision, or sophisticated combination procedures. Patients whose plans were marginally dependent on the refund should rebudget; everyone else should proceed as planned.